Lenalidomide: all 818 studies that test it
Page 7 of 9. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.
- Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System LymphomaCompletedNCT01956695Phase 2
- Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT01955499Phase 1
- Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple MyelomaTerminatedNCT01954784Phase 1
- Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)CompletedNCT01936532Phase 2
- Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01904643Phase 1
- Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01886859Phase 1
- R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCLCompletedNCT01865110Phase 3
- Lenalidomide Plus Rituximab (R) in Non Follicular NHLStatus unknownNCT01830478Phase 2
- Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular LymphomaActive, not recruitingNCT01829568Phase 1
- Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS SyndromeCompletedNCT01816620Phase 2
- Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell LymphomasCompletedNCT01788189Phase 1/2
- A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell LymphomaCompletedNCT01766583Phase 1
- Ipilimumab and Lenalidomide in Advanced CancerCompletedNCT01750983Phase 1
- Lenalidomide After Allo TransplantTerminatedNCT01750762Phase 1
- SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM PatientsCompletedNCT01749969Phase 1
- Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid MalignanciesTerminatedNCT01744912Phase 1
- An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)TerminatedNCT01742793Phase 1
- Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCLCompletedNCT01737177Phase 2
- Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic LymphomaCompletedNCT01732861Phase 1
- Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT01729104Phase 1
- Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.CompletedNCT01718379Phase 2
- Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent NeuroblastomaActive, not recruitingNCT01711554Phase 1
- Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLLCompletedNCT01703364Phase 1/2
- Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide MaintenanceCompletedNCT01702831Phase 2
- Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed MyelomaStatus unknownNCT01686386Phase 1/2
- Lenalidomide Plus Chemotherapy for AMLCompletedNCT01681537Phase 1
- Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic SyndromeStatus unknownNCT01673308Phase 2
- A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular LymphomaCompletedNCT01650701Phase 3
- Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceWithdrawnNCT01647165Phase 2
- Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular LymphomaCompletedNCT01644799Phase 1
- POEMS Syndrome Treatment With LenalidomideCompletedNCT01639898Phase 2
- Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT01629082Phase 1
- Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple MyelomaTerminatedNCT01617213Phase 2
- Phase I Study of Lenalidomide in Patients With Acute LeukemiaTerminatedNCT01615042Phase 1
- Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + LenalidomideTerminatedNCT01604031Phase 1
- Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Phase 2
- Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple MyelomaCompletedNCT01583283Phase 1
- Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell LymphomaCompletedNCT01582776Phase 1/2
- Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard InductionCompletedNCT01578954Phase 1
- Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT01562405Phase 1
- A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic LeukemiaCompletedNCT01558167Phase 1/2
- A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line TherapyCompletedNCT01556776Phase 3
- The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).Status unknownNCT01556477Phase 2
- Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous LymphomaCompletedNCT01556035Phase 2
- Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple MyelomaTerminatedNCT01555281Phase 1/2
- Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma PatientsStatus unknownNCT01554852Phase 3
- Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)CompletedNCT01553786Phase 2
- Lenalidomide and Dexamethasone in Primary Plasma Cell LeukemiaCompletedNCT01553357Phase 2
- Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic CancerCompletedNCT01547260Phase 1/2
- Lenalidomide as Second-line Treatment for Advanced Hepatocellular CarcinomaCompletedNCT01545804Phase 2
- Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular LymphomaCompletedNCT01542918Phase 1
- Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple MyelomaCompletedNCT01530594Phase 3
- Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple MyelomaTerminatedNCT01518465Phase 2
- ACVDL Treatment for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01481194Phase 2
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic TransplantationCompletedNCT01460420Phase 1/2
- Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)CompletedNCT01459211Phase 2
- Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple MyelomaCompletedNCT01450215Phase 2
- Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)Active, not recruitingNCT01446133Phase 2
- Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) PatientsCompletedNCT01440582Phase 1
- Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeCompletedNCT01433965Phase 1
- Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin LymphomaCompletedNCT01429025Phase 1
- Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple MyelomaTerminatedNCT01421927Phase 1
- A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin LymphomaStatus unknownNCT01412307Phase 1/2
- Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous LupusCompletedNCT01408199Phase 4
- Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLCompletedNCT01400685Phase 1
- Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular LymphomaCompletedNCT01393756Phase 2
- Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate CancerCompletedNCT01378091Phase 1
- Lenalidomide in Patients With Chronic Myelomonocytic LeukemiaStatus unknownNCT01368757Phase 1/2
- Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT01359657Phase 1
- Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid TumorsCompletedNCT01352962Phase 1
- Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)CompletedNCT01352338Phase 1/2
- Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular CarcinomaTerminatedNCT01348503Phase 1
- Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular LymphomaTerminatedNCT01307605Phase 2
- Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin LymphomaStatus unknownNCT01307592Phase 2
- Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)CompletedNCT01301820Phase 2
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT01297764Phase 1/2
- Lenalidomide in Kaposi Disease Associated With HIV InfectionTerminatedNCT01282047Phase 2
- Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic LeukemiaWithdrawnNCT01271283Phase 2
- Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure PatientsCompletedNCT01270932Phase 2
- Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic TransplantCompletedNCT01264315Phase 2
- Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck CancerCompletedNCT01254617Phase 1
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01246622Phase 1
- Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to TreatmentCompletedNCT01246557Phase 1/2
- Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic SyndromeCompletedNCT01243476Phase 3
- Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose DexamethasoneCompletedNCT01237249Phase 2
- Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine GliomasCompletedNCT01222754Phase 1
- Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins LymphomaCompletedNCT01207921Phase 1
- Frontline Therapy in de Novo Multiple Myeloma Patients Under 65CompletedNCT01206205Phase 2
- Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian CancerTerminatedNCT01202890Phase 1
- LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)TerminatedNCT01198054Phase 4
- Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly DiagnosedCompletedNCT01194791Phase 2
- Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 YearsCompletedNCT01191060Phase 3
- Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular LymphomaWithdrawnNCT01180569Phase 1/2
- A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell LymphomaCompletedNCT01169298Phase 1
- Lenalidomide and Cetuximab in Patients With Advanced Solid TumorsStatus unknownNCT01166035Phase 1/2
- Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma PatientsCompletedNCT01160107Phase 2
- Lenalidomide and Paclitaxel in Advanced Solid TumorsStatus unknownNCT01155505Phase 1
- Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic LeukemiaCompletedNCT01133743Phase 2
- Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell LymphomaStatus unknownNCT01132989Phase 2